<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M875</article-id>
      <article-id pub-id-type="publisher-id">molbank-2015-M875</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>(8<italic>R</italic>,10a<italic>S</italic>)-Methyl 2,4-diamino-8-(<italic>tert</italic>-butyl)-6-oxo-6,8,10,10a-tetrahydrooxazolo[3&#x2032;&#x2032;,4&#x2032;&#x2032;:1&#x2032;,5&#x2032;]-pyrrolo[3&#x2032;,4&#x2032;:5,6]pyrido[2,3-<italic>d</italic>]pyrimidine-10a-carboxylate</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Clarke</surname>
            <given-names>Georgia</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moloney</surname>
            <given-names>Mark G.</given-names>
          </name>
          <xref rid="c1-molbank-2015-M875" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Haider</surname>
            <given-names>Norbert</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2015-M875">Chemistry Research Laboratory, Department of Chemistry, The University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, UK</aff>
      <author-notes>
        <corresp id="c1-molbank-2015-M875"><label>*</label> Author to whom correspondence should be addressed; E-Mail: <email>mark.moloney@chem.ox.ac.uk</email>; Tel.: +44-186-527-5656; Fax: +44-186-528-5002.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>11</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2015</year>
      </pub-date>
      <volume>2015</volume>
      <issue>4</issue>
      <elocation-id>M875</elocation-id>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>09</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>11</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>A fused polyheterocyclic derivative is available by annulation of a tetramate scaffold, and has been shown to have some Gram-negative, but not Gram-positive, antibacterial activity.</p>
      </abstract>
      <kwd-group>
        <kwd>antibacterial</kwd>
        <kwd>tetramate</kwd>
        <kwd>polyheterocycle</kwd>
        <kwd>heteroaromatic</kwd>
        <kwd>annulation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-molbank-2015-M875" sec-type="intro">
      <title>1. Introduction</title>
      <p>It is now widely appreciated that the antibacterial drug pipeline is poorly populated [<xref ref-type="bibr" rid="B1-molbank-2015-M875">1</xref>], and that the emergence of antibacterial resistance creates a constant need for new drugs [<xref ref-type="bibr" rid="B2-molbank-2015-M875">2</xref>,<xref ref-type="bibr" rid="B3-molbank-2015-M875">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2015-M875">4</xref>]. Historically, natural products have provided a crucial start point in antibacterial drug discovery [<xref ref-type="bibr" rid="B5-molbank-2015-M875">5</xref>] and still remain worthy of investigation. The tetramic acid core is a template widely found in natural products with antibacterial activity [<xref ref-type="bibr" rid="B6-molbank-2015-M875">6</xref>,<xref ref-type="bibr" rid="B7-molbank-2015-M875">7</xref>] and although the core tetramic motif tends to have no antibacterial activity [<xref ref-type="bibr" rid="B8-molbank-2015-M875">8</xref>], we have shown that an appropriately modified tetramic core can exhibit high levels of antibacterial activity [<xref ref-type="bibr" rid="B9-molbank-2015-M875">9</xref>,<xref ref-type="bibr" rid="B10-molbank-2015-M875">10</xref>,<xref ref-type="bibr" rid="B11-molbank-2015-M875">11</xref>,<xref ref-type="bibr" rid="B12-molbank-2015-M875">12</xref>,<xref ref-type="bibr" rid="B13-molbank-2015-M875">13</xref>]. Some fused ring quinoline-containing compounds which are structurally similar to tetramates, such as pyrrolo[3,4-<italic>c</italic>]quinoline-1,3-dione derivatives, exhibit inhibition of Gram-positive and Gram-negative bacteria [<xref ref-type="bibr" rid="B14-molbank-2015-M875">14</xref>] and, of interest to us, was the construction of a similarly fused heterocyclic-tetramate and an examination of its bioactivity.</p>
    </sec>
    <sec id="sec2-molbank-2015-M875" sec-type="results">
      <title>2. Results and Discussion</title>
      <sec id="sec2dot1-molbank-2015-M875">
        <title>2.1. Chemical Synthesis </title>
        <p>The desired compound used bicyclic template <bold>1</bold>, prepared as reported [<xref ref-type="bibr" rid="B15-molbank-2015-M875">15</xref>], which could be readily converted to enamine <bold>2</bold> by treatment with trimethyl orthoformate and an aromatic amine in refluxing dichloromethane, and similar to a recently reported protocol [<xref ref-type="bibr" rid="B16-molbank-2015-M875">16</xref>] (<xref ref-type="scheme" rid="molbank-2015-M875-sch001">Scheme 1</xref> and <xref ref-type="fig" rid="molbank-2015-M875-f001">Figure 1</xref>). The pure product <bold>2</bold> could be obtained by column chromatography, as a mixture of <italic>E</italic>- and <italic>Z</italic>-isomers, with the major being that as shown. This material was readily reacted with 2,4,6-triaminopyrimidine <bold>3</bold> which, under prolonged heating in DMSO, gave heterocyclic product <bold>4</bold> in 47% yield, assigned on the basis-detailed NMR (HSQC, HMBC) analysis. The bulk structure was confirmed by clear correlations of 0.88 (-C(C<italic>H</italic><sub>3</sub>)<sub>3</sub>)) with a carbon at 23.96, of 4.81 (C-2<italic>H</italic>) with 97.37 (<italic>C</italic>-2), of 8.61 (1H, s, C-10<italic>H</italic>) with 131.3 (<italic>C</italic>-10), and of the coupled pair at 3.25 and 4.89 (C-4H<italic>H</italic>) with 68.93 (<italic>C</italic>-4). This HMBC data gives the expected correlations, but does not secure the regiochemistry of the original addition to enamine <bold>2</bold>. The structure of this compound could not be confirmed by NOE analysis either, but is assigned on the basis of comparison with the outcome of related annulation processes [<xref ref-type="bibr" rid="B17-molbank-2015-M875">17</xref>] and by chemical shift calculations (MestReNova&#x2122;) of 8.42 ppm (observed, 8.61) for C(10)H and of 131.2 ppm (observed, 131.0) for C(10).</p>
      </sec>
      <sec id="sec2dot2-molbank-2015-M875">
        <title>2.2. Antibacterial Activity </title>
        <p>Biological activity of this derivative was assessed against Gram-positive <italic>S. aureus</italic> and Gram-negative <italic>E. coli</italic>, in triplicate by hole-plate bioassay, with cephalosporin C as a positive control, after overnight incubation in a 1:1 mixture of DMSO and water with a concentration of 4 mg mL<sup>&#x2212;1</sup>. Compound <bold>4</bold> showed activity against <italic>E. coli</italic>, but not against <italic>S. aureus</italic>, in contrast to most tetramates, which generally display selective Gram positive activity (<xref ref-type="app" rid="app1-molbank-2015-M875">Table S1 and Figure S9</xref> in the supplementary materials) [<xref ref-type="bibr" rid="B9-molbank-2015-M875">9</xref>,<xref ref-type="bibr" rid="B10-molbank-2015-M875">10</xref>,<xref ref-type="bibr" rid="B11-molbank-2015-M875">11</xref>,<xref ref-type="bibr" rid="B12-molbank-2015-M875">12</xref>].</p>
      </sec>
    </sec>
    <sec id="sec3-molbank-2015-M875">
      <title>3. Experimental Section </title>
      <sec>
        <title>(8R,10aS)-Methyl 2,4-diamino-8-(tert-butyl)-6-oxo-6,8,10,10a-tetrahydrooxazolo[3'',4'':1',5']-pyrrolo[3',4':5,6]pyrido[2,3-d]pyrimidine-10a-carboxylate <italic><bold>4</bold></italic></title>
        <p>Under a nitrogen atmosphere, tetramic acid <bold>1</bold> (225 mg, 1.0 mmol) was dissolved in anhydrous DCM (10 mL), and <italic>para</italic>-bromoaniline (189 mg, 1.1 mmol) and trimethyl orthoformate (0.12 mL, 1.0 mmol) were added. The solution was refluxed at 45 &#xB0;C for five hours, following the reaction using TLC. The reaction mixture was then cooled to room temperature and the DCM was removed in vacuo to give the crude product. Flash column chromatography (DCM&#x2013;EtOAc 4:1) was used to purify the crude product to give <bold>2</bold> as a yellow solid in the ratio of 1.8:1 diastereomers (325 mg, 84%) [<xref ref-type="bibr" rid="B18-molbank-2015-M875">18</xref>].</p>
        <p>Compound <bold>2</bold> (70 mg, 0.16 mmol) was dissolved in DMSO (5 mL), and 2,4,6-triaminopyrimidine (26 mg, 0.21 mmol) was added. The solution was heated to 100 &#xB0;C for 24 h, following the reaction using TLC. The reaction mixture was then cooled to room temperature and diluted with EtOAc (20 mL). Brine (15 mL) was added, and the organic layer was extracted, and then washed with brine (15 mL) four more times. The EtOAc was removed <italic>in vacuo</italic> to give the crude product. This was then columned on aluminium oxide (EtOAc&#x2013;MeOH 5:1) to give the product <bold>4</bold> as a pink solid (28 mg, 47%); <bold>&#x3B4;H</bold> (500 MHz, MeOD) 0.88 (9H, s, -C(C<italic>H</italic><sub>3</sub>)<sub>3</sub>), 3.25 (1H, d, <italic>J</italic> = 8.6, C-4<italic>H</italic>H&#x2032;), 3.62 (3H, s, -OC<italic>H</italic><sub>3</sub>), 4.81 (1H, s, C-2<italic>H</italic>), 4.89 (1H, d, <italic>J</italic> = 8.6, C-4H<italic>H</italic>'), 8.61 (1H, s, C-10<italic>H</italic>); <bold>&#x3B4;C</bold> (500 MHz, MeOD) 23.96 (-C(<italic>C</italic>H<sub>3</sub>)<sub>3</sub>), 34.98 (-<italic>C</italic>(CH<sub>3</sub>)<sub>3</sub>), 52.35 (-O<italic>C</italic>H<sub>3</sub>), 68.93 (<italic>C</italic>-4), 75.60 (<italic>C</italic>-5), 97.37 (<italic>C</italic>-2), 105.7, 117.9 (<italic>C</italic>-7, <italic>C</italic>-11), 131.3 (<italic>C</italic>-10), 163.8, 164.4, 164.6, 168.1 (<italic>C</italic>-6, <italic>C</italic>-12, <italic>C</italic>-14, <italic>C</italic>-16), 168.8 (<italic>C</italic>-9), 172.8 (<italic>C</italic>-8); <bold><italic>m</italic>/<italic>z</italic></bold> (ESI<sup>+</sup>) 373.2 ([M + H]<sup>+</sup> 100%); <bold>HRMS</bold> (ESI<sup>+</sup>) found 373.16187 ([M + H]<sup>+</sup>) requires 373.16188; <bold>&#x3BD;<sub>max</sub></bold> 3344 (N-H), 3184 (N-H), 2957 (C-H), 1715 (C=O), 1607 (C=O), 1547, 1488, 1260, 1207, 818; <bold>m.p.</bold> 190&#x2013;192 &#xB0;C.</p>
        <p>In the <xref ref-type="app" rid="app1-molbank-2015-M875">Supplementary Information</xref>, <xref ref-type="app" rid="app1-molbank-2015-M875">Figures S1&#x2013;S8</xref> give NMR spectra, <xref ref-type="app" rid="app1-molbank-2015-M875">Table S1</xref> gives the results of the antibacterial assay, and <xref ref-type="app" rid="app1-molbank-2015-M875">Figure S9</xref> gives the standard calibration curve.</p>
      </sec>
    </sec>
    <sec id="sec4-molbank-2015-M875" sec-type="conclusions">
      <title>4. Conclusions </title>
      <p>Annulation of a bicyclic tetramate to generate a multiply fused heterocylic system can be achieved rapidly and in good yield, and this system possesses some antibacterial bioactivity.</p>
    </sec>
  </body>
  <back>
  <app-group>
    <app id="app1-molbank-2015-M875">
        <title>Supplementary materials</title>
	  	  <supplementary-material id="molbank-2015-M875-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M875-s001.pdf">
   <label>Supplementary File 1</label>
</supplementary-material>
        <supplementary-material id="molbank-2015-M875-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M875-s002-mod.mol">
   <label>Supplementary File 2</label>
</supplementary-material>
        <supplementary-material id="molbank-2015-M875-s003" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M875-s002.mol">
   <label>Supplementary File 3</label>
</supplementary-material>
    </app>
</app-group>
    <notes>
      <title>Author Contributions</title>
      <p>GC designed, conducted and analysed the data from experiments, and MGM analysed the data from experiments and wrote the manuscript.</p>
    </notes>
    <notes>
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest. </p>
    </notes>
    <ref-list>
      <title>References and Notes</title>
      <ref id="B1-molbank-2015-M875">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boucher</surname>
              <given-names>H.W.</given-names>
            </name>
            <name>
              <surname>Talbot</surname>
              <given-names>G.H.</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Bradley</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Guidos</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>R.N.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>B.E.</given-names>
            </name>
            <name>
              <surname>Bonomo</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>10 &#xD7; &#x2032;20 Progress&#x2014;development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America</article-title>
          <source>Clin. Infect. Dis.</source>
          <year>2013</year>
          <volume>56</volume>
          <fpage>1685</fpage>
          <lpage>1694</lpage>
          <pub-id pub-id-type="doi">10.1093/cid/cit152</pub-id>
          <pub-id pub-id-type="pmid">23599308</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2015-M875">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Pollastri</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Schiffer</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Peet</surname>
              <given-names>N.P.</given-names>
            </name>
          </person-group>
          <article-title>The challenge of developing robust drugs to overcome resistance</article-title>
          <source>Drug Discovery Today</source>
          <year>2011</year>
          <volume>16</volume>
          <fpage>755</fpage>
          <lpage>761</lpage>
          <pub-id pub-id-type="doi">10.1016/j.drudis.2011.07.001</pub-id>
          <pub-id pub-id-type="pmid">21784168</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2015-M875">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hurdle</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Neill</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Chopra</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>R.E.</given-names>
            </name>
          </person-group>
          <article-title>Targeting bacterial membrane function: An underexploited mechanism for treating persistent infections</article-title>
          <source>Nat. Rev. Microbiol.</source>
          <year>2011</year>
          <volume>9</volume>
          <fpage>62</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1038/nrmicro2474</pub-id>
          <pub-id pub-id-type="pmid">21164535</pub-id>
        </citation>
      </ref>
      <ref id="B4-molbank-2015-M875">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms of antibiotic resistance</article-title>
          <source>Chem. Commun.</source>
          <year>2011</year>
          <volume>47</volume>
          <fpage>4055</fpage>
          <lpage>4061</lpage>
          <pub-id pub-id-type="doi">10.1039/c0cc05111j</pub-id>
          <pub-id pub-id-type="pmid">21286630</pub-id>
        </citation>
      </ref>
      <ref id="B5-molbank-2015-M875">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Lister</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>May-Dracka</surname>
              <given-names>T.L.</given-names>
            </name>
          </person-group>
          <article-title>Natural products as leads for antibacterial drug discovery</article-title>
          <source>Biorg. Med. Chem. Lett.</source>
          <year>2014</year>
          <volume>24</volume>
          <fpage>413</fpage>
          <lpage>418</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2013.12.059</pub-id>
          <pub-id pub-id-type="pmid">24388805</pub-id>
        </citation>
      </ref>
      <ref id="B6-molbank-2015-M875">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Royles</surname>
              <given-names>B.J.L.</given-names>
            </name>
          </person-group>
          <article-title>Naturally-occurring tetramic acids&#x2014;Structure, isolation, and synthesis</article-title>
          <source>Chem. Rev.</source>
          <year>1995</year>
          <volume>95</volume>
          <fpage>1981</fpage>
          <lpage>2001</lpage>
          <pub-id pub-id-type="doi">10.1021/cr00038a009</pub-id>
        </citation>
      </ref>
      <ref id="B7-molbank-2015-M875">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schobert</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Schlenk</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Tetramic and tetronic acids: An update on new derivatives and biological aspects</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2008</year>
          <volume>16</volume>
          <fpage>4203</fpage>
          <lpage>4221</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2008.02.069</pub-id>
          <pub-id pub-id-type="pmid">18334299</pub-id>
        </citation>
      </ref>
      <ref id="B8-molbank-2015-M875">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeong</surname>
              <given-names>Y.-C.</given-names>
            </name>
            <name>
              <surname>Moloney</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Tetramic acids as bioactive templates: Synthesis, tautomeric and antibacterial behaviour</article-title>
          <source>Synlett</source>
          <year>2009</year>
          <fpage>2487</fpage>
          <lpage>2491</lpage>
        </citation>
      </ref>
      <ref id="B9-molbank-2015-M875">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeong</surname>
              <given-names>Y.-C.</given-names>
            </name>
            <name>
              <surname>Moloney</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Antibacterial barbituric acid analogues inspired from natural 3-acyltetramic acids; synthesis, tautomerism and structure and physicochemical property-antibacterial activity relationships</article-title>
          <source>Molecules</source>
          <year>2015</year>
          <volume>20</volume>
          <fpage>3582</fpage>
          <lpage>3627</lpage>
          <pub-id pub-id-type="doi">10.3390/molecules20033582</pub-id>
          <pub-id pub-id-type="pmid">25710842</pub-id>
        </citation>
      </ref>
      <ref id="B10-molbank-2015-M875">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeong</surname>
              <given-names>Y.-C.</given-names>
            </name>
            <name>
              <surname>Moloney</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Bikadi</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hazai</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>A detailed study of antibacterial 3-acyltetramic acids and 3-acylpiperidine-2,4-diones</article-title>
          <source>ChemMedChem</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>1826</fpage>
          <lpage>1837</lpage>
          <pub-id pub-id-type="doi">10.1002/cmdc.201402093</pub-id>
          <pub-id pub-id-type="pmid">24838989</pub-id>
        </citation>
      </ref>
      <ref id="B11-molbank-2015-M875">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeong</surname>
              <given-names>Y.-C.</given-names>
            </name>
            <name>
              <surname>Anwar</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Moloney</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Bikadi</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hazai</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, antibiotic activity and structure-activity relationship study of some 3-enaminetetramic acids</article-title>
          <source>Biorg. Med. Chem. Lett.</source>
          <year>2014</year>
          <volume>24</volume>
          <fpage>1901</fpage>
          <lpage>1906</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2014.03.013</pub-id>
          <pub-id pub-id-type="pmid">24679702</pub-id>
        </citation>
      </ref>
      <ref id="B12-molbank-2015-M875">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeong</surname>
              <given-names>Y.-C.</given-names>
            </name>
            <name>
              <surname>Moloney</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antibacterial activity of monocyclic 3-carboxamidotetramic acids</article-title>
          <source>Beilstein J. Org. Chem.</source>
          <year>2013</year>
          <volume>9</volume>
          <fpage>1899</fpage>
          <lpage>1906</lpage>
          <pub-id pub-id-type="doi">10.3762/bjoc.9.224</pub-id>
          <pub-id pub-id-type="pmid">24204399</pub-id>
        </citation>
      </ref>
      <ref id="B13-molbank-2015-M875">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeong</surname>
              <given-names>Y.-C.</given-names>
            </name>
            <name>
              <surname>Anwar</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Moloney</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Bikadi</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hazai</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Natural product inspired antibacterial tetramic acid libraries with dual enzyme target activity</article-title>
          <source>Chem. Sci.</source>
          <year>2013</year>
          <volume>4</volume>
          <fpage>1008</fpage>
          <lpage>1015</lpage>
          <pub-id pub-id-type="doi">10.1039/C2SC21713A</pub-id>
        </citation>
      </ref>
      <ref id="B14-molbank-2015-M875">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xia</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Idhayadhulla</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>Y.R.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Wee</surname>
              <given-names>Y.-J.</given-names>
            </name>
          </person-group>
          <article-title>Microwave-assisted synthesis of diverse pyrrolo[3,4-<italic>c</italic>]quinoline-1,3-diones and their antibacterial activities</article-title>
          <source>ACS Comb. Sci.</source>
          <year>2014</year>
          <volume>16</volume>
          <fpage>333</fpage>
          <lpage>341</lpage>
          <pub-id pub-id-type="doi">10.1021/co500002s</pub-id>
          <pub-id pub-id-type="pmid">24749663</pub-id>
        </citation>
      </ref>
      <ref id="B15-molbank-2015-M875">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrews</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Brewster</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Crapnell</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Ibbett</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Moloney</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Prout</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Watkin</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Regioselective Dieckmann cyclisations leading to enantiopure highly functionalised tetramic acid derivatives</article-title>
          <source>J. Chem. Soc., Perkin Trans. 1</source>
          <year>1998</year>
          <fpage>223</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="doi">10.1039/a706014i</pub-id>
        </citation>
      </ref>
      <ref id="B16-molbank-2015-M875">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oshega</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Paponov</surname>
              <given-names>B.V.</given-names>
            </name>
            <name>
              <surname>Omelchenko</surname>
              <given-names>I.V.</given-names>
            </name>
            <name>
              <surname>Shishkin</surname>
              <given-names>O.V.</given-names>
            </name>
          </person-group>
          <article-title>One-pot three-component synthesis of 3-cyano-4-methyl-2,6-dioxopyridine amino enones</article-title>
          <source>Mendeleev Commun.</source>
          <year>2015</year>
          <volume>25</volume>
          <fpage>133</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="doi">10.1016/j.mencom.2015.03.019</pub-id>
        </citation>
      </ref>
      <ref id="B17-molbank-2015-M875">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Condensation of 2,4-diamino-6(1<italic>H</italic>)-pyrimidinone with 2-(aminomethylene)cyclopentanone</article-title>
          <source>J. Org. Chem.</source>
          <year>1984</year>
          <volume>49</volume>
          <fpage>3226</fpage>
          <lpage>3227</lpage>
          <pub-id pub-id-type="doi">10.1021/jo00191a040</pub-id>
        </citation>
      </ref>
      <ref id="B18-molbank-2015-M875">
        <label>18.</label>
        <note>
		<p>Data for compound <bold>2</bold>: <bold>&#x3B4;</bold><bold>H</bold> (500 MHz, CDCl<sub>3</sub>) Major: 0.88 (9H, s, -C(C<italic>H</italic><sub>3</sub>)<sub>3</sub>), 3.46 (1H, d, <italic>J</italic> = 8.8, C-4<italic>H</italic>H'), 3.72 (3H, s, -OC<italic>H</italic><sub>3</sub>), 4.78 (1H, d, <italic>J</italic> = 8.8, C-4H<italic>H</italic>'), 4.81 (1H, s, C-2<italic>H</italic>), 7.00&#x2013;7.05 (2H, m, ArH), 7.46&#x2013;7.51 (2H, m, ArH), 8.10 (1H, d, <italic>J</italic> = 13.2, C-10<italic>H</italic>), 10.93 (1H, d, <italic>J</italic> = 12.9, -N<italic>H</italic>Ar), Minor: 0.87 (9H, s, -C(C<italic>H</italic><sub>3</sub>)<sub>3</sub>), 3.45 (1H, d, <italic>J</italic> = 8.8, C-4<italic>H</italic>H'), 3.73 (3H, s, -OC<italic>H</italic><sub>3</sub>), 4.77 (1H, d, <italic>J</italic> = 8.8, C-4H<italic>H</italic>'), 4.84 (1H, s, C-2<italic>H</italic>), 7.00&#x2013;7.05 (2H, m, ArH), 7.46&#x2013;7.51 (2H, m, ArH), 8.02 (1H, s, C-10<italic>H</italic>), 10.82 (1H, br s, -N<italic>H</italic>Ar); <bold>&#x3B4;</bold><bold>C</bold> (500 MHz, CDCl<sub>3</sub>): Major: 24.73 (-C(<italic>C</italic>H<sub>3</sub>)<sub>3</sub>), 35.29 (-<italic>C</italic>(CH<sub>3</sub>)<sub>3</sub>), 53.23 (-O<italic>C</italic>H<sub>3</sub>), 68.42 (<italic>C</italic>-4), 78.04 (<italic>C</italic>-5), 98.18 (<italic>C</italic>-2), 99.06 (<italic>C</italic>-7), 119.1 (<italic>C</italic>-13), 120.1 (<italic>C</italic>-15), 133.3 (<italic>C</italic>-14), 136.7 (<italic>C</italic>-12), 146.3 (<italic>C</italic>-10), 168.3 (<italic>C</italic>-9), 177.6 (<italic>C</italic>-8), 189.0 (<italic>C</italic>-6), Minor: 24.77 (-C(<italic>C</italic>H<sub>3</sub>)<sub>3</sub>), 35.35 (-<italic>C</italic>(CH<sub>3</sub>)<sub>3</sub>), 53.24 (-O<italic>C</italic>H<sub>3</sub>), 68.32 (<italic>C</italic>-4), 77.29 (<italic>C</italic>-5), 98.28 (<italic>C</italic>-2), 99.05 (<italic>C</italic>-7), 119.3 (<italic>C</italic>-13), 120.3 (<italic>C</italic>-15), 133.3 (<italic>C-</italic>14), 136.7 (<italic>C</italic>-12), 147.0 (<italic>C</italic>-10), 168.3 (<italic>C</italic>-9), 174.2 (<italic>C</italic>-8), 192.5 (<italic>C</italic>-6); <bold><italic>m/z</italic></bold> (ESI<sup>+</sup>) 437.1 ([M + H]<sup>+</sup> 100%); <bold>HRMS</bold> (ESI<sup>+</sup>) found 436.0777, 438.0661 ([M + H]<sup>+</sup>) requires 436.0634, 438.0616; <bold>&#x3BD;</bold><bold><sub>max</sub></bold> 3214 (N-H), 2959 (C-H), 2871 (C-H), 1747 (C=O), 1708, (C=O) 1619 (C=O), <bold>1474</bold>, <italic>1300</italic>, 1205, 731; <bold>m.p.</bold> 116&#x2013;117 &#xB0;C.</p>
		</note>
      </ref>
    </ref-list>
    <sec sec-type="display-objects">
      <title>Figure and Scheme</title>
      <fig id="molbank-2015-M875-sch001" position="float">
        <object-id pub-id-type="pii">molbank-2015-M875-sch001_Scheme 1</object-id>
        <label>Scheme 1</label>
        <caption>
          <p>Annulation of tetramate <bold>1</bold> to product <bold>4</bold>.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M875-sch001.tif"/>
      </fig>
      <fig id="molbank-2015-M875-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Structure of compound <bold>4</bold>.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2015-M875-g001.tif"/>
      </fig>
    </sec>
  </back>
</article>
